BioStock: Curasight gets first milestone payment from Curium

The prostate cancer partnership with Curium marks the most pivotal moment for the radiopharmaceutical focused biotech company Curasight to date. Now, the company has announced a first milestone payment under the deal, for the validation of GMP manufacturing of finished product. BioStock reached out to CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/02/curasight-gets-first-milestone-payment-from-curium/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se